Anthem Biosciences has debuted at Rs 723.10 on the BSE, up by 153.1 points or 26.86% from its issue price of Rs 570.00.
The scrip is currently trading at Rs. 724.75, up by 154.75 points or 27.15% from its issue price.
It has touched a high and low of Rs. 746.70 and Rs. 723.05 respectively. So far 30.51 lakh shares were traded on the counter.
The offering, which was open for subscription between July 14, 2025 and July 16, 2025 was subscribed 67.42 times. The issue price was fixed at Rs 570 per share i.e. at upper end of price band of Rs 540-570 apiece.
Anthem is into innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. Anthem's business also manufactures and sale of specialty ingredients. It also manufactures and sells complex specialised fermentation-based active pharmaceutical ingredients (APIs), including probiotics, enzymes, peptides, and biosimilars.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.40 |
| Dr. Reddys Lab | 1282.15 |
| Cipla | 1304.70 |
| Zydus Lifesciences | 960.00 |
| Lupin | 2249.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: